Difference between revisions of "Renal neoplasms with TSC/mTOR pathway mutations"
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
*[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/> | *[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/> | ||
*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/> | *[[Low-grade oncocytic tumour]].<ref name=pmid35203531/> | ||
*[[Renal cell carcinoma with fibromyomatous stroma]].<ref name=pmid37899532>{{cite journal |authors=Shah RB, Mehra R |title=Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up |journal=Adv Anat Pathol |volume=31 |issue=2 |pages=105–117 |date=March 2024 |pmid=37899532 |doi=10.1097/PAP.0000000000000419 |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 04:11, 20 March 2024
Renal neoplasms with TSC/mTOR pathway mutations is a diverse group of kidney tumours.
Kidney tumours with TSC/mTOR mutations:
- Eosinophilic solid and cystic renal cell carcinoma.[1]
- Eosinophilic vacuolated tumour.[1]
- Low-grade oncocytic tumour.[1]
- Renal cell carcinoma with fibromyomatous stroma.[2]
References
- ↑ 1.0 1.1 1.2 Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O (January 2022). "TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background". Biomedicines 10 (2). doi:10.3390/biomedicines10020322. PMC 8869370. PMID 35203531. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869370/.
- ↑ Shah RB, Mehra R (March 2024). "Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up". Adv Anat Pathol 31 (2): 105–117. doi:10.1097/PAP.0000000000000419. PMID 37899532.